Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 May 2022 | Story Nonkululeko Nxumalo
Open Access 3


Should the UFS continue to subscribe to academic journals that are behind a paywall?

On 12 May 2022, the University of the Free State (UFS) held an online seminar on Open Science, posing this question.

The seminar was facilitated by Prof Corli Witthuhn, Vice-Rector: Research and Internationalisation, who was joined by the following experts: Colleen Campbell from the Max Planck Digital Library (MPDL) in Munich, Germany, where she coordinates the Open Access 2020 Initiative; Ellen Tise, Senior Director of Library and Information Services at Stellenbosch University (SU); Glen Truran, Director of the South African National Library and Information Consortium (SANLiC); and Charlie Molepo, Deputy Director at the UFS Library Service. The discussion centred around the issues of accessing and publishing academic content behind a paywall, and what open access initiatives are doing to transition scholarly work to an open access (OA) paradigm.

“Publishing academic content behind a paywall not only limits access to scholarly work, but also prevents research output from being visible and making maximum impact,” the university stated.

Paywalls vs Open Access

A paywall is a figurative wall used to limit access to certain prestigious academic content. Overcoming this wall usually means a one-time purchase option where the reader buys the content from the publisher, or it could be subscription-based where you pay a subscription fee for a fixed period. OA, on the other hand, seeks to make any scholarly work freely available to anyone interested in accessing it, including those who cannot afford the subscription fees.

"Currently, authors are required to give up copyright of their research articles to publishers. We want to move to a fully open paradigm where authors can redeem and openly license their articles so that they are free to share, use, and reuse their work so that science can move forward faster. By making it open, we gain a wider possible readership that will help improve the quality of science,” Campbell said.

Furthermore, not only are publishers making a profit from subscription fees, but they also benefit significantly from hefty publishing and author fees.

“Researchers are paying to publish their research output, and libraries are paying to access it in what is known as double-dipping by publishers, leading to what we term ‘serial crisis’. Research institutions pay twice and still do not see their research widely available to be read.”

Transformative Agreements 

The panel explained the use of transformative agreements as a strategy to achieve full OA publishing. This strategy includes OA initiatives that organise investments around open research communication, demanding price transparency from publishers, as well as reorganising workflow and building up the capacity to make OA a default.

With Truran presenting statistics on OA in South Africa, he highlighted that “only 46% of South African journals are available freely, the rest are still out of reach of those who cannot afford to pay the costs associated with paywalls”. Tise touched on some negotiation principles for a transformational transition to OA. “Inclusivity and social justice must be core. Publishers must have an equity, diversity, and inclusion plan that addresses the challenges of researchers in the Global South.”

Should the UFS continue to subscribe to academic journals that are behind a paywall? 
Truran answered this question by saying: “If we’re going to cancel subscriptions, then we should do it in unity and at the appropriate time. At the same time giving transformative agreements a go."

In his closing remarks, Molepo clarified the university’s stance on OA: “The UFS has taken a decision to publish all our journals in-house. We have flipped from subscription to full OA, and in the process, have seen a huge improvement in terms of citation. The impact of those journals has improved drastically from 2015 to 2021. We are content with that. The route to OA is the route this university should be taking,” he said.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept